{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "claude-opus-4-5",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Mirikizumab",
        "role": {
          "code": "Investigational Product",
          "codeSystem": "USDM",
          "decode": "Investigational Product"
        },
        "instanceType": "StudyIntervention",
        "description": "Investigational product for ulcerative colitis treatment",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "role": {
          "code": "Placebo",
          "codeSystem": "USDM",
          "decode": "Placebo"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo for mirikizumab",
        "administrationIds": [
          "admin_2"
        ]
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Mirikizumab",
        "instanceType": "AdministrableProduct",
        "doseForm": {
          "code": "Solution",
          "codeSystem": "USDM",
          "decode": "Solution"
        },
        "strength": "Not specified in provided content",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Eli Lilly and Company"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Mirikizumab Induction",
        "instanceType": "Administration",
        "dose": "Not specified in provided content",
        "doseFrequency": "Every 2 weeks",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "12 weeks (Induction Treatment Period)"
      },
      {
        "id": "admin_2",
        "name": "Mirikizumab Maintenance",
        "instanceType": "Administration",
        "dose": "Not specified in provided content",
        "doseFrequency": "Every 2 weeks",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "40 weeks (Maintenance Treatment Period, Week 12 to Week 52)"
      },
      {
        "id": "admin_3",
        "name": "Mirikizumab Extension Induction",
        "instanceType": "Administration",
        "dose": "Not specified in provided content",
        "doseFrequency": "Every 2 weeks",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "14 weeks (Extension Induction Period for nonresponders)"
      },
      {
        "id": "admin_4",
        "name": "Mirikizumab Extension Maintenance",
        "instanceType": "Administration",
        "dose": "Not specified in provided content",
        "doseFrequency": "Every 2 weeks",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "26 weeks (Extension Maintenance Period)"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Mirikizumab",
        "instanceType": "Substance",
        "description": "Active pharmaceutical ingredient - IL-23p19 antagonist"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 2,
      "productCount": 1,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Mirikizumab",
        "role": "Investigational Product",
        "description": "Investigational product for ulcerative colitis treatment"
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching placebo for mirikizumab"
      }
    ],
    "products": [
      {
        "name": "Mirikizumab",
        "doseForm": "Solution for injection",
        "strength": "Not specified in provided content",
        "manufacturer": "Eli Lilly and Company"
      }
    ],
    "substances": [
      {
        "name": "Mirikizumab",
        "description": "Active pharmaceutical ingredient - IL-23p19 antagonist"
      }
    ],
    "administrations": [
      {
        "name": "Mirikizumab Induction",
        "dose": "Not specified in provided content",
        "frequency": "Every 2 weeks",
        "route": "Subcutaneous or Intravenous",
        "duration": "12 weeks (Induction Treatment Period)"
      },
      {
        "name": "Mirikizumab Maintenance",
        "dose": "Not specified in provided content",
        "frequency": "Every 2 weeks",
        "route": "Subcutaneous or Intravenous",
        "duration": "40 weeks (Maintenance Treatment Period, Week 12 to Week 52)"
      },
      {
        "name": "Mirikizumab Extension Induction",
        "dose": "Not specified in provided content",
        "frequency": "Every 2 weeks",
        "route": "Subcutaneous or Intravenous",
        "duration": "14 weeks (Extension Induction Period for nonresponders)"
      },
      {
        "name": "Mirikizumab Extension Maintenance",
        "dose": "Not specified in provided content",
        "frequency": "Every 2 weeks",
        "route": "Subcutaneous or Intravenous",
        "duration": "26 weeks (Extension Maintenance Period)"
      }
    ],
    "devices": []
  }
}